• March 12, 2014 - N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial
  • October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
  • April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
  • March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
  • October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
  • October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Oral S-Nitrosoglutathione Reductase Inhibitor N91115: A Multiple Ascending-Dose Study In Healthy Subjects
  • October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Intravenous S-NitrosoglutathioneReductaseInhibitor N6022: An Ascending-Dose Study in Subjects Homozygous for the F508del-CFTRMutation
  • October 4, 2014 - Pharmacological Correction and Acute Inhibition of GSNOR Results in Improved In Vitro CFTR Function
  • October 4, 2014 - Neutrophil Elastase-Mediated CFTR Damage is Rescued by Intracellular Bioavailable GSNO
  • March 21, 2014 - Primary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctors
More posters

October 4, 2014

Pharmacological Correction and Acute Inhibition of GSNOR Results in Improved In Vitro CFTR Function

Rachel C. Angers, Kirsten M. Look, Sarah C. Mutka, Peter F. Bove, and Sherif E. Gabriel

Cystic fibrosis (CF) is a multifaceted disease caused by genetic defects in the cystic fibrosis transmembrane conductance regulator (CFTR). The lung phenotype of
patients with CF includes excessive mucus secretion, inflammation, and frequent infections stemming from altered Na+/Cl- transport across the epithelia.

In addition, CF patients also exhibit decreased lung concentrations of endogenous Snitrosoglutathione (GSNO) compared to non-diseased individuals. More…(550Kb)

Comments are closed.